Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Ovarian and Endometrial Cancer — An Interview with Dr Shannon Westin on the Current Management Paradigm

52:35
 
Share
 

Manage episode 501435154 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Shannon N Westin, including the following topics:

  • Biomarker testing and utility in ovarian cancer (OC) (0:00)
  • Selection of a PARP inhibitor for the treatment of OC (9:18)
  • Addition of immunotherapy to up-front treatment of OC (15:50)
  • Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
  • Selection of treatment for recurrent OC (21:46)
  • Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
  • Adjuvant therapy for EC (32:28)
  • Utility of lenvatinib/pembrolizumab in EC (35:08)
  • Clinical findings supporting the potential use of selinexor for EC (39:42)
  • Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
  • Management of adverse effects associated with T-DXd (49:49)

CME information and select publications

  continue reading

740 episodes

Artwork
iconShare
 
Manage episode 501435154 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Shannon N Westin, including the following topics:

  • Biomarker testing and utility in ovarian cancer (OC) (0:00)
  • Selection of a PARP inhibitor for the treatment of OC (9:18)
  • Addition of immunotherapy to up-front treatment of OC (15:50)
  • Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
  • Selection of treatment for recurrent OC (21:46)
  • Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
  • Adjuvant therapy for EC (32:28)
  • Utility of lenvatinib/pembrolizumab in EC (35:08)
  • Clinical findings supporting the potential use of selinexor for EC (39:42)
  • Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
  • Management of adverse effects associated with T-DXd (49:49)

CME information and select publications

  continue reading

740 episodes

Todos os episódios

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play